{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:29:37Z","timestamp":1790990977376,"version":"4.1.0"},"reference-count":61,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Objectives: To verify medication-related osteonecrosis of the jaw (MRONJ) frequency among patients with plasma cell myeloma (PCM) that had been treated with bisphosphonates, to identify predisposing factors that could influence the development of osteonecrosis. Methods: This observational retrospective study was performed at the Department of Hematology of Hospital Center of Porto (CHUP), Portugal. Results: The study population (n = 112) had a 15.2% (n = 17) prevalence of osteonecrosis. Clinically, bone exposure was the most frequently observed sign, present in 100% (n = 17) of the patients, followed by inflammation in 82.4% (n = 14), orofacial pain in 70.6% (n = 12), suppuration in 47.1% (n = 8), and intra or extra-oral fistula in 17.6% (n = 3) of the cases. The most frequent triggering local factor was dental extraction (82.4%). There was a dependence between the presence of extractions and the development of MRONJ (p &lt; 0.001) but not with the time elapsed from the initiation of infusions with BPs and dental extractions (p = 0.499). In the sample of patients with multiple myeloma (MM), 13.8% were found to be more likely to develop MRONJ after an extraction. Conclusions: The most common local predisposing factor was dental extraction. No dependence was observed between the development of osteonecrosis and the time elapsed from the beginning of treatment with bisphosphonates infusions to surgical procedures.<\/jats:p>","DOI":"10.3390\/jcm13092679","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T07:04:14Z","timestamp":1714633454000},"page":"2679","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Osteonecrosis of the Jaw Associated with Bisphosphonates Infusion for Treatment of Plasma Cell Myeloma\u2014A Retrospective Observational Study of Northern Portuguese Population"],"prefix":"10.3390","volume":"13","author":[{"given":"Sara Sousa","family":"Ferreira","sequence":"first","affiliation":[{"name":"UNIPRO, Unidade de Investiga\u00e7\u00e3o de Patologia e Reabilita\u00e7\u00e3o Oral, Instituto Universit\u00e1rio de Ci\u00eancias da Sa\u00fade do Norte (IUCS-CESPU), 4585-116 Gandra, Portugal"},{"name":"Oral Medicine and Oral Surgery Department, Instituto Universit\u00e1rio de Ci\u00eancias da Sa\u00fade do Norte (IUCS-N), 4585-116 Gandra, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9820-5319","authenticated-orcid":false,"given":"Jos\u00e9 Barbas do","family":"Amaral","sequence":"additional","affiliation":[{"name":"Oral Medicine and Oral Surgery Department, Instituto Universit\u00e1rio de Ci\u00eancias da Sa\u00fade do Norte (IUCS-N), 4585-116 Gandra, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0423-0976","authenticated-orcid":false,"given":"Jos\u00e9 J\u00falio","family":"Pacheco","sequence":"additional","affiliation":[{"name":"UNIPRO, Unidade de Investiga\u00e7\u00e3o de Patologia e Reabilita\u00e7\u00e3o Oral, Instituto Universit\u00e1rio de Ci\u00eancias da Sa\u00fade do Norte (IUCS-CESPU), 4585-116 Gandra, Portugal"},{"name":"Oral Medicine and Oral Surgery Department, Instituto Universit\u00e1rio de Ci\u00eancias da Sa\u00fade do Norte (IUCS-N), 4585-116 Gandra, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6693-4426","authenticated-orcid":false,"given":"Filomena","family":"Salazar","sequence":"additional","affiliation":[{"name":"UNIPRO, Unidade de Investiga\u00e7\u00e3o de Patologia e Reabilita\u00e7\u00e3o Oral, Instituto Universit\u00e1rio de Ci\u00eancias da Sa\u00fade do Norte (IUCS-CESPU), 4585-116 Gandra, Portugal"},{"name":"Oral Medicine and Oral Surgery Department, Instituto Universit\u00e1rio de Ci\u00eancias da Sa\u00fade do Norte (IUCS-N), 4585-116 Gandra, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8938-1297","authenticated-orcid":false,"given":"Lu\u00eds","family":"Monteiro","sequence":"additional","affiliation":[{"name":"UNIPRO, Unidade de Investiga\u00e7\u00e3o de Patologia e Reabilita\u00e7\u00e3o Oral, Instituto Universit\u00e1rio de Ci\u00eancias da Sa\u00fade do Norte (IUCS-CESPU), 4585-116 Gandra, Portugal"},{"name":"Oral Medicine and Oral Surgery Department, Instituto Universit\u00e1rio de Ci\u00eancias da Sa\u00fade do Norte (IUCS-N), 4585-116 Gandra, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin. Proc."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2011-06-358812","article-title":"Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN)","volume":"118","author":"Palumbo","year":"2011","journal-title":"Blood"},{"key":"ref_3","unstructured":"(2018, May 13). Portugal Doen\u00e7as Oncol\u00f3gicas em N\u00fameros\u20142014. Programa Nacional para as Doen\u00e7as Oncol\u00f3gicas. Lisbon, Portugal: Direc\u00e7\u00e3o-Geral da Sa\u00fade, Minist\u00e9rio da Sa\u00fade. Available online: https:\/\/www.dgs.pt\/estatisticas-de-saude\/estatisticas-de-saude\/publicacoes\/portugal-doencas-oncologicas-em-numeros-2014.aspx."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"693","DOI":"10.4065\/81.5.693","article-title":"Monoclonal gammopathy of undetermined significance, Waldenstr\u00f6m macroglobulinemia, AL amyloidosis, and related plasma cell disorders: Diagnosis and treatment","volume":"81","author":"Rajkumar","year":"2006","journal-title":"Mayo Clin. Proc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"key":"ref_6","first-page":"478","article-title":"Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: Biological insights and early treatment strategies","volume":"2013","author":"Landgren","year":"2013","journal-title":"ASH Educ. Program Book"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ajh.21845","article-title":"IgM multiple myeloma: Disease definition, prognosis, and differentiation from Waldenstrom\u2019s macroglobulinemia","volume":"85","author":"Schuster","year":"2010","journal-title":"Am. J. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1182\/blood-2013-05-505487","article-title":"Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden","volume":"123","author":"Turesson","year":"2014","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"Vidriales","year":"2007","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/leu.2012.189","article-title":"Suppression of uninvolved immunoglobulins defined by heavy\/light chain pair suppression is a risk factor for progression of MGUS","volume":"27","author":"Katzmann","year":"2013","journal-title":"Leukemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/annonc\/mdi235","article-title":"Myeloma bone disease: Pathophysiology and management","volume":"16","author":"Terpos","year":"2005","journal-title":"Ann. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1158\/1078-0432.CCR-10-1804","article-title":"Advances in the biology and treatment of bone disease in multiple myeloma","volume":"17","author":"Raje","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_15","first-page":"CD003188","article-title":"Bisphosphonates in multiple myeloma: A network meta-analysis","volume":"5","author":"Mhaskar","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_16","first-page":"CD008455","article-title":"Interventions for treating bisphospho-nate-related osteonecrosis of the jaw (BRONJ)","volume":"2","author":"Rollason","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00774-016-0810-7","article-title":"Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw","volume":"35","author":"Yoneda","year":"2017","journal-title":"J. Bone Miner. Metab."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Rugani, P., Walter, C., Kirnbauer, B., Acham, S., Begus-Nahrman, Y., and Jakse, N. (2016). Prevalence of medication-related osteonecrosis of the jaw in patients with breast cancer, prostate cancer, and multiple myeloma. Dent. J., 4.","DOI":"10.3390\/dj4040032"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jcms.2007.06.008","article-title":"\u201cBis-phossy jaws\u201d\u2013high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw","volume":"36","author":"Warnke","year":"2008","journal-title":"J. Cranio-Maxillofac. Surg."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jcms.2011.05.003","article-title":"Bisphosphonate-related osteonecrosis of the jaws\u2013characteristics, risk factors, clinical features, localization and impact on oncological treatment","volume":"40","author":"Otto","year":"2012","journal-title":"J. Cranio-Maxillofac. Surg."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/0022034510397196","article-title":"Risk factors for osteonecrosis of the jaws: A case-control study from the CONDOR dental PBRN","volume":"90","author":"Barasch","year":"2011","journal-title":"J. Dent. Res."},{"key":"ref_26","first-page":"b147","article-title":"Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: A review of 282 patients","volume":"77","author":"Bonacina","year":"2011","journal-title":"J. Can. Dent. Assoc."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/COC.0b013e3182155fcb","article-title":"A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates","volume":"35","author":"Tu","year":"2012","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"319","DOI":"10.5114\/aoms.2015.50964","article-title":"Incidence and risk predictors for osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates","volume":"11","author":"Kos","year":"2015","journal-title":"Arch. Med. Sci. AMS"},{"key":"ref_29","first-page":"13","article-title":"A population based study of multiple myeloma patients with medication-related osteonecrosis of the jaw","volume":"21","author":"Auzina","year":"2019","journal-title":"Stomatol. Balt. Dent. Maxillofac. J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6222s","DOI":"10.1158\/1078-0432.CCR-06-0843","article-title":"Molecular mechanisms of action of bisphosphonates: Current status","volume":"12","author":"Roelofs","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S8756-3282(99)00116-7","article-title":"Bisphosphonates: From the laboratory to the clinic and back again","volume":"25","author":"Russell","year":"1999","journal-title":"Bone"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos. Int."},{"key":"ref_33","first-page":"e582","article-title":"Exposed necrotic bone in 183 patients with bisphosphonate-related osteonecrosis of the jaw: Associated clinical characteristics","volume":"22","author":"Bagan","year":"2017","journal-title":"Med. Oral Patol. Oral y Cir. Bucal"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","article-title":"Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment","volume":"63","author":"Marx","year":"2005","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1093\/annonc\/mdm370","article-title":"A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients","volume":"18","author":"Jadu","year":"2007","journal-title":"Ann. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.bone.2009.07.011","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: A key role of inflammation?","volume":"45","author":"Lesclous","year":"2009","journal-title":"Bone"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.oraloncology.2010.11.007","article-title":"Surgery-triggered and non surgery-triggered Bisphosphonate-related Osteonecrosis of the Jaws (BRONJ): A retrospective analysis of 567 cases in an Italian multicenter study","volume":"47","author":"Vescovi","year":"2011","journal-title":"Oral Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ygyno.2008.11.029","article-title":"Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies","volume":"112","author":"Fehm","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.080205","article-title":"Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates","volume":"23","author":"Hoff","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3816\/CLM.2008.n.013","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Definition and management of the risk related to zoledronic acid","volume":"8","author":"Cafro","year":"2008","journal-title":"Clin. Lymphoma Myeloma"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.ijom.2012.06.020","article-title":"Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: A cohort study","volume":"41","author":"Yamazaki","year":"2012","journal-title":"Int. J. Oral Maxillofac. Surg."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1200\/JCO.2009.21.9584","article-title":"Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw","volume":"27","author":"Vahtsevanos","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1365-2141.2006.06230.x","article-title":"Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: A single-centre experience in 303 patients","volume":"134","author":"Zervas","year":"2006","journal-title":"Br. J. Haematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1200\/JCO.2008.16.2768","article-title":"Bisphosphonate-related osteonecrosis of the jaws: A case-control study of risk factors in breast cancer patients","volume":"26","author":"Kyrgidis","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.joms.2013.02.016","article-title":"Oral health risk factors for bisphosphonate-associated jaw osteonecrosis","volume":"71","author":"Tsao","year":"2013","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/sj.bdj.2009.5","article-title":"Dental extractions and bisphosphonates: The assessment, consent and management, a proposed algorithm","volume":"206","author":"Malden","year":"2009","journal-title":"Br. Dent. J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.joms.2007.11.032","article-title":"Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: A case-control study","volume":"66","author":"Wessel","year":"2008","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.2005.04.2465","article-title":"Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors","volume":"24","author":"Badros","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_50","unstructured":"(2018, May 13). A Sa\u00fade dos Portugueses 2016. Lisbon, Portugal: Dire\u00e7\u00e3o-Geral da Sa\u00fade, Minist\u00e9rio da Sa\u00fade. Available online: https:\/\/comum.rcaap.pt\/bitstream\/10400.26\/18278\/1\/A%20Sa%C3%BAde%20dos%20Portugueses%202016.pdf."},{"key":"ref_51","unstructured":"(2018, May 13). Programa Nacional para a Diabetes 2017. Lisbon, Portugal: Dire\u00e7\u00e3o-Geral da Sa\u00fade, Minist\u00e9rio da Sa\u00fade. Available online: https:\/\/www.dgs.pt\/programa-nacional-para-a-diabetes\/relatorios-e-publicacoes.aspx."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.14219\/jada.archive.2009.0049","article-title":"Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy","volume":"140","author":"Sedghizadeh","year":"2009","journal-title":"J. Am. Dent. Assoc."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00784-010-0507-6","article-title":"The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes\u2014In vitro study","volume":"16","author":"Pabst","year":"2012","journal-title":"Clin. Oral Investig."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.archoralbio.2010.11.003","article-title":"Bisphosphonate effects on the behaviour of oral epithelial cells and oral fibroblasts","volume":"56","author":"Ravosa","year":"2011","journal-title":"Arch. Oral Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1749-6632.2010.05835.x","article-title":"Potential pathophysiological mechanisms in osteonecrosis of the jaw","volume":"1218","author":"Landesberg","year":"2011","journal-title":"Ann. New York Acad. Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40902-021-00310-w","article-title":"Characteristics of patients with osteonecrosis of the jaw with oral versus intravenous bisphosphonate treatment","volume":"43","author":"Lee","year":"2021","journal-title":"Maxillofac. Plast. Reconstr. Surg."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.joms.2009.01.007","article-title":"The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: So many hypotheses, so few data","volume":"67","author":"Allen","year":"2009","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1532-3382(12)70046-5","article-title":"Antiresorptives and osteonecrosis of the jaw","volume":"12","author":"Yamashita","year":"2012","journal-title":"J. Evid. Based Dent. Pract."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.12968\/bjcn.2003.8.Sup6.12554","article-title":"HCN: The detrimental effects of smoking on wound healing","volume":"8","author":"Whiteford","year":"2003","journal-title":"Br. J. Community Nurs."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1902\/jop.2000.71.12.1874","article-title":"Cigar, pipe, and cigarette smoking as risk factors for periodontal disease and tooth loss","volume":"71","author":"Albandar","year":"2000","journal-title":"J. Periodontol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/sarh.2002.33724b","article-title":"Pathogenesis and natural history of osteonecrosis","volume":"32","author":"Chang","year":"2002","journal-title":"Semin. Arthritis Rheum."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/9\/2679\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:38:41Z","timestamp":1760107121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/9\/2679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,2]]},"references-count":61,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["jcm13092679"],"URL":"https:\/\/doi.org\/10.3390\/jcm13092679","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,2]]}}}